Neural Regeneration Research ›› 2012, Vol. 7 ›› Issue (16): 1220-1227.

Previous Articles     Next Articles

Granulocyte-macrophage colony-stimulating factor-transfected bone marrow stromal cells for the treatment of ischemic stroke

Xingjian Lin1, Yingdong Zhang1, 2, Weiguo Liu1, Jingde Dong1, Jie Lu1, Qing Di1, Jingping Shi1   

  1. 1 Nanjing Medical University, Affiliated Nanjing Brain Hospital, Department of Neurology, Nanjing 210029, Jiangsu Province, China
    2 Nanjing Medical University, Affiliated Nanjing First Hospital, Department of Neurology, Nanjing 210029, Jiangsu Province, China
  • Received:2012-01-29 Revised:2012-04-27 Online:2012-06-05 Published:2012-06-05
  • Contact: Yingdong Zhang, M.D., Chief physician, Nanjing Medical University, Affiliated Nanjing Brain Hospital, Department of Neurology, Nanjing 210029, Jiangsu Province, China; Nanjing Medical University, Affiliated Nanjing First Hospital, Department of Neurology, Nanjing 210029, Jiangsu Province, China zhangyingdong2006@ yahoo.com.cn
  • About author:Xingjian Lin☆, M.D., Asso-ciate chief physician, Nanjing Medical University, Affiliated Nanjing Brain Hospital, Department of Neurology, Nanjing 210029, Jiangsu Province, China Xingjian Lin and Weiguo Liu contributed equally to this paper.

PDF

723

Abstract:

Adult, male, Sprague-Dawley rats were injected with granulocyte-macrophage colony-stimulating factor-transfected bone marrow stromal cells (GM-CSF-BMSCs) into the ischemic boundary zone at 24 hours after onset of middle cerebral artery occlusion. Results showed reduced infarct volume, decreased number of apoptotic cells, improved neurological functions, increased angiogenic factor expression, and increased vascular density in the ischemic boundary zone in rats that underwent GM-CSF-BMSCs transplantation compared with the BMSCs group. Experimental findings suggested that GM-CSF-BMSCs could serve as a potential therapeutic strategy for ischemic stroke and are superior to BMSCs alone.

Key words: